作者: Peter Vestergaard
DOI: 10.1007/S12018-007-9002-2
关键词: Aromatase 、 Type 2 diabetes 、 Bone mineral 、 Calcium metabolism 、 Bone remodeling 、 Pharmacology 、 Type 1 diabetes 、 Tamoxifen 、 Medicine 、 Internal medicine 、 Endocrinology 、 Adverse effect
摘要: Drugs may affect bone turnover and density in many ways. However, the disease for which drugs are administered also contribute to loss. Infection with human immunodeficiency virus leads a loss of mineral, while treatment highly active antiretroviral therapy does not seem further Type 1 diabetes is associated decrease type 2 an increase. The new class thiazolidinediones (glitazones) has been increased mineral. In breast cancer treatment, tamoxifen newer aromatase inhibitors through serum oestradiol Strong analgesics (opioids) mineral inhibition gonadotrophins weak such as non-steroidal anti-inflammatory increase effect on prostaglandin system. possibly risk falls, fractures. Proton pump lead decreased calcium absorption thus